glp·helper
glphelper.com/zepbound/washington/vancouver
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Vancouver, WA

Verified Zepbound providers in Vancouver, WA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
35
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Washington
35 of 35 shown

Find a Zepbound provider in Washington.

Every entry is checked against the NPI registry and the Washington medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Washington city · /zepbound/washington/{city}
§ 03Getting Zepbound in Washington
35 providers · 4 metros

How a prescription works in Washington.

You don’t have to leave Washington to start. Because tirzepatide isn't a controlled substance, a Washington-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 35 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Washington
Zepbound (tirzepatide) is a GLP-1, not a controlled substance, so a Washington-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
WA-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Washington can prescribe Zepbound. The 35 providers below are checked against the NPI registry and the Washington board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Washington Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Washington’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Washington

Diagnosed diabetes reaches 8.6% of adults in Washington.

of Washington adults have obesity
31.5%
diagnosed diabetes
8.6%

Age-adjusted estimates for Washington, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight losswhat to expect week by week
§ 05Support around Zepbound in Vancouver
6 gyms

The prescription is one part. Here is the rest, in Vancouver.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Vancouver, WA, ordered as the registry lists them, never by who pays us.

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

MUV Fitness SE Portland
GYM
4.7 on Google · 3267 reviews
10414 SE Washington St
Website
East Portland Community Center
FITNESS
4.4 on Google · 1099 reviews
740 SE 106th Ave
Website
Common Ground Wellness Cooperative
FITNESS
4.8 on Google · 944 reviews
5010 NE 33rd Ave
Website
Planet Fitness
GYM
4.0 on Google · 880 reviews
8024 E Mill Plain Blvd
Website
Cascade Athletic Club - Vancouver
FITNESS
4.5 on Google · 875 reviews
16096 SE 15th St
Website
Lloyd Athletic Club
GYM
4.6 on Google · 828 reviews
815 NE Halsey St Suite B Studio 1
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Karlie Abrams, RD
RD
Registered dietitian
400 Ne Mother Joseph Pl
Call 360-514-2320NPI 1932615523
Amy Anderson, MS, RDN, CDN, CDCES
RD
Registered dietitian
2211 Ne 139Th St
Call 360-487-1251NPI 1689325367
Kali Anderson, RD
RD
Registered dietitian
6800 Ne Vancouver Mall Dr Unit B
Call 813-838-2268NPI 1346042280
Angelina Andriola, RDN
RD
Registered dietitian
8301B 5Th Ave Ne
Call 206-799-7010NPI 1972203388
Jan Apland-Curtis
RD
Registered dietitian
1601 E Fourth Plain Blvd
Call 360-397-8000NPI 1073728184
Carrie Beck, MPH, RDN, CD
RD
Registered dietitian
13818 Se 36Th St
Call 360-314-5511NPI 1346159977
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Washington

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Washington

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]